局限性前列腺癌立体定向体部放疗后的前列腺特异性抗原动力学:范围综述与荟萃分析
该范围综述与荟萃分析检索MEDLINE、Scopus和Embase,纳入33项记录共9949例患者,分析局限性前列腺癌SBRT后PSA斜率、最低值、反跳和生化失败。SBRT后PSA初始快速下降、随时间放缓,最低值中位数0.24 ng/mL,低于常规放疗;良性PSA反跳见于30%患者。
要点
- SBRT后PSA最低值中位数0.24 ng/mL,低于常规放疗。
- 良性PSA反跳见于30%患者,中位发生时间14.8个月,中位幅度0.5 ng/mL。
- ADT使用与PSA反跳频率呈显著负相关(r=-0.49;p=0.046)。
核心结论
- 局限性前列腺癌SBRT后的PSA动力学与其他已确立的放疗方式不同,良性PSA反跳非常常见。
- 临床医生应了解这些因素并对患者进行相应宣教,以避免不必要的痛苦或挽救治疗。
研究设计与样本
- 范围综述与荟萃分析,检索MEDLINE、Scopus和Embase中报告前列腺SBRT后PSA斜率、最低值、反跳和生化失败的研究。
- 共纳入33项记录(45%为前瞻性研究),涵盖9949例患者。
- SBRT剂量范围为32-50 Gy,分4-5次照射。
- 总体中位随访时间(范围)为41(15-74)个月。
- 雄激素剥夺治疗(ADT)使用比例为0-38%。
主要发现
- SBRT后PSA初始快速下降、随时间放缓,最终最低值低于常规放疗,中位值(范围)为0.24(0.1-0.6)ng/mL,达到中位时间(范围)为33.1(6-54)个月。
- 试验中最高SBRT剂量与PSA最低值呈负相关(r=-0.59;p<0.001)。
- 所有研究中良性PSA反跳发生率为30%,中位时间(范围)为14.8(9-36)个月,中位幅度(范围)为0.5(0.3-1.1)ng/mL。
- PSA反跳与剂量、最低值及生化失败均无显著相关性。
- ADT使用与PSA反跳频率呈显著负相关(r=-0.49;p=0.046)。
临床怎么用
- 作者指出,临床医生应了解SBRT后PSA动力学特点并对患者进行相应宣教,以防止不必要的痛苦或挽救治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic body radiotherapy (SBRT) is emerging as a valuable treatment modality for localized prostate cancer, with promising biochemical progression-free survival rates. Longitudinal assessment of prostate-specific antigen (PSA) is the mainstay of follow-up after treatment. PSA kinetics and dynamics are well-established in the context of brachytherapy and conventionally fractionated radiotherapy, yet little is known in the context of prostate SBRT. METHODS: A review of available literature in MEDLINE, Scopus, and Embase was performed, focusing on studies reporting PSA slope, nadir, bounce, and biochemical failure after prostate SBRT. RESULTS: Thirty-three records (45 % prospective) encompassing 9949 patients were included. SBRT dose ranged from 32-50 Gy in 4-5 fractions and overall median follow-up time (range) was 41 (15-74) months. Use of androgen deprivation therapy ranged from 0-38 %. SBRT was characterized by a steep initial decline of PSA, slowing down over time and ultimately yielding a lower nadir in comparison with conventional radiotherapy, with a median value (range) of 0.24 (0.1-0.6) ng/mL after a median time (range) of 33.1 (6-54) months. There was an inverse correlation between the highest SBRT dose in a trial and PSA nadir (r = - 0.59; p < 0.001). Benign PSA bounce occurred in 30 % of patients across all studies, after a median time (range) of 14.8 (9-36) months and with a median size (range) of 0.5 (0.3-1.1) ng/mL. There was no significant correlation between bounce and dose, nadir nor biochemical failure. There was, however, a significant inverse correlation between ADT use and PSA bounce frequency (r = -0.49; p = 0.046). CONCLUSION: PSA kinetics and dynamics after SBRT for localized prostate cancer are different from those in other established radiotherapy modalities. Benign PSA bounce is very common. Clinicians should be aware of these factors and patients should be counseled accordingly, preventing unnecessary distress or salvage treatment.
引用
- Dejonckheere CS, Caglayan L, Glasmacher AR, et al. Prostate-specific antigen kinetics after stereotactic body radiotherapy for localized prostate cancer: A scoping review and meta-analysis. Radiother Oncol. 2024. PMID: 39557124. doi:10.1016/j.radonc.2024.110642
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。